Tresiba is a once-daily basal insulin with a duration of action beyond 42 hours, allowing for flexibility in day-to-day dosing time when needed, without compromising efficacy or risk of hypoglycaemia.
It is the first insulin to offer people with diabetes the flexibility in the timing of insulin administration on occasions when administration at the same time of day is not possible.
A particular problem people with diabetes face while taking insulin is a condition of low blood-sugar called hypoglycaemia.
Hypoglycaemic episodes are unpleasant and experiencing them might lead to a lower compliance with insulin therapy, leading to increased risk of long-term complications.
Night-time hypoglycaemia is of particular concern for people living with diabetes, as these are often unpredictable and difficult to detect and react upon.
The lower rates of night-time hypoglycaemia with Tresiba will allay some of these concerns and encourage patients and physicians to aim for more ambitious glucose targets.
Tresiba reduces blood glucose levels with a lower risk of night-time hypoglycaemia compared to other molecules available in the market.
During the launch of Tresiba in India, Melvin Oscar D'souza, Managing Director, Novo Nordisk India, said: "We have been constantly innovating and discovering new molecules that bring in significant clinical benefits to patients that would enable them to lead a healthy and productive life."
"In current insulin treatments, people with diabetes are required to take their long-acting insulin at around the same time each day," said Dr Raman Shetty, Clinical Medical and Regulatory Director, Novo Nordisk India.
"However, the mode of action of insulin degludec ensures that, on occasions when this is not possible, people with diabetes can alter the time they take their insulin without compromising their diabetes control or putting themselves at increased risk of hypoglycaemia.
"However it is important to note that patients must consult their doctor and strictly follow their advice about any change in their treatment, said Dr Shetty.
Tresiba will be made available in FlexTouch, the only prefilled pen with an easy touch button, enabling doses of up to 80 units in a single injection.
On this occasion the company also introduced a "Patient education kit" which would act as a ready reckoner to diabetes management.
The patient kit would cover a broad array of important topics, such as: the A-Z of diabetes, diet and nutrition, the benefits of regular exercise, importance of foot care and a variety of other health issues that are appropriate for the person with diabetes.
--IBNS (Posted on 03-10-2013)